Indian medical device manufacturers have expressed strong optimism following the United States’ decision to lower import tariffs on a broad category of medical products from India to 18%, effective January 2026. The tariff reduction, finalised after several rounds of trade negotiations and India’s demonstrated progress in aligning with USFDA quality and regulatory requirements, removes a significant cost barrier that previously limited the competitiveness of Indian exports in the world’s largest medical device market.

The affected categories include high-volume items such as surgical disposables, diagnostic kits, orthopaedic implants, cardiovascular devices, respiratory equipment, and hospital consumables segments where Indian manufacturers have built strong manufacturing capabilities under the PLI scheme and Make-in-India framework. The 18% rate is viewed as far more favourable compared to earlier effective duties (often 25–30% including additional fees), giving Indian companies a meaningful price advantage over competitors from China and other high-tariff origins.

Rajiv Nath, Forum Coordinator of the Association of Indian Medical Device Industry (AiMeD), described the development as “a game-changer for Indian medtech exports.” He noted that the tariff relief would directly improve margins, enable more aggressive pricing in the US market, and encourage further investment in capacity expansion and quality systems. Several large manufacturers, including those producing syringes, catheters, stents, and diagnostic reagents, have already indicated plans to ramp up shipments and explore new US distributor partnerships.

The reduction is widely seen as a direct result of sustained efforts by the Indian government and industry to address US concerns around quality, documentation, and post-market surveillance. Over the past 2–3 years, Indian firms have significantly increased USFDA approvals, reduced Form 483 observations, and strengthened pharmacovigilance systems factors that helped pave the way for this tariff concession.

The Indian medical device sector, currently valued at around $12–14 billion domestically and growing rapidly, has been aggressively targeting export markets. The US accounts for a growing share of these exports, and the tariff cut is expected to accelerate momentum in 2026–2027. Industry estimates suggest the move could add ₹2,000–3,000 crore in incremental export value annually in the medium term, while creating additional skilled jobs in manufacturing clusters across Gujarat, Maharashtra, Tamil Nadu, Andhra Pradesh, and Haryana.

The government has welcomed the development as validation of its localisation and quality improvement policies. Officials indicated that further tariff reductions or zero-duty access could be negotiated in future rounds if India continues to demonstrate compliance and quality leadership.